Division provides total solution for smoother, more efficient trials
Research Triangle Park, NC – February 11, 2016 –Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, today announced the launch of its new Professional Services Division. Expanding its commitment to customers, Cenduit created this group to establish a new operating model that engages sponsors throughout the entire clinical trial and provides hands-on experience when it comes to managing and enhancing Interactive Response Technology (IRT) systems.
As the world’s largest IRT specialist, Cenduit has deep expertise in clinical domain, IRT system integration and people across multiple vendors, CROs and sponsors. Promoting collaboration across its IRT services and platforms, Cenduit’s Professional Services Division encompasses research and development, enables more effective patient and drug management, provides eClinical integration, BI Analytics and solutions for customization to provide a seamless user experience.
“The Cenduit Professional Services Division goes above and beyond for its clients by working together with our sales, project management and operations teams to create a customized system that exceeds the expectations of the original design plan,” said Praveen Chand, director of professional services, Cenduit. “I am excited to be heading up this team that was created to keep sponsors as the focal point, providing a total solution that makes the IRT process dramatically smoother and more efficient, with innovative solutions and quality product delivery – from study build through maintenance and closeout.”
In addition to the collaboration between various business functions at Cenduit, the Professional Services Division will also weigh in on particularly complex protocols or integrations with third-party systems that may require extra support to achieve trial success. The new division will also manage Cenduit’s custom reporting tool to accommodate complex reporting requests that project management may need to fulfill for a client.
“Professional Services is another tool in Cenduit’s toolkit, available to jump into study build or maintenance as-needed, providing one-off support for particularly challenging requests where additional expertise and resources are needed,” added Chand.
How Cenduit’s Professional Services Division will benefit clients:
About Cenduit
Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, is the largest IRT specialist in the world with the expertise to empower sponsors for success by implementing a completely personalized system that puts them in control of their clinical trials. With the needs of investigator sites and patients top of mind, Cenduit offers clinical supply chain intelligence and clinical operations know-how through its IRT-driven services: patient randomization, patient reminders, drug supply management, and eClinical integration. Cenduit has offices in the US, UK, Switzerland, India, and Japan, and global clinical trial experience in more than 100 countries, interacting with more than 600,000 patients at more than 32,000 sites. For additional information, visit Cenduit online at www.cenduit.com; on Twitter @CenduitLLC or on LinkedIn at www.LinkedIn.com/Company/Cenduit.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.